ZNF423

ZNF423 is a multi-zinc-finger transcription factor that integrates several developmental signaling inputs at chromatin, acting as a context-dependent node in differentiation programs and in disease (PMID:12393497, PMID:19345331, PMID:33646306). Through distinct zinc-finger surfaces it physically engages multiple partners: its terminal fingers (ZF29-30) bind Early B-cell Factor (EBF1/OLF1) to antagonize EBF1 transactivation, while internal regions bind SMAD1 and SMAD4 to transduce BMP signaling toward targets such as Xvent-2 (PMID:12393497, PMID:23764426). Genome-wide, ZNF423 occupies canonical EBF1-binding sites even in the absence of EBF1, depletes activating histone marks at those loci, and selectively blocks EBF1-dependent transactivation, including repression of the TGFB1 promoter (PMID:33646306). In neuroblastoma it associates with the RARα/RXRα nuclear receptor complex and is required for retinoic acid-induced differentiation (PMID:19345331). ZNF423 also participates in the DNA damage response, colocalizing with TIP60 at nuclear damage foci alongside CEP164 and NPHP10, with its loss sensitizing cells to DNA-damaging agents (PMID:22863007). In breast cancer it is an estrogen-inducible activator of the BRCA1 promoter and of the mitotic kinases VRK1 and PBK, with intronic SNPs near estrogen response elements modulating these responses and downstream drug sensitivity (PMID:23764426, PMID:30937657). Beyond DNA-directed roles, ZNF423 acts as an RNA-binding protein that binds AU-rich elements in the BCAT1 3'-UTR to promote autophagy via the IRE1-XBP1-RIDD axis (PMID:32938905). Its own expression is controlled epigenetically: promoter DNA methylation and nucleosome occupancy gate adipocyte precursor commitment, and hypomethylation drives aberrant ZNF423 expression in B-precursor ALL where it enforces B-cell maturation arrest (PMID:24081948, PMID:29067487). ZNF423 has both oncogenic activity—cooperating with BCR/ABL in CML blast crisis and acting through a UBR5-ZNF423 fusion in nasopharyngeal carcinoma—and developmental functions, with patient-derived and engineered zinc-finger variants producing allele-dependent midline brain abnormalities in mice (PMID:19234145, PMID:23878065, PMID:28893945, PMID:32925911).

1. 2002 Medium

   Established ZNF423 as a dual-function transcriptional regulator that bridges EBF antagonism and BMP/SMAD signaling, defining its first molecular partnerships and the domain (ZF29-30) responsible for EBF binding.

   Evidence Protein binding and transactivation assays with cellular fractionation

   PMID:12393497

   Open questions at the time

   • No genome-wide binding map
   • Structural basis of SMAD versus EBF engagement undefined
2. 2005 Medium

   Mapped the C-terminal six zinc fingers as the module required to modulate EBF activity and linked ZNF423 overexpression to upregulation of EBF target genes in tumors, connecting the molecular activity to an oncogenic readout.

   Evidence Domain-deletion transactivation reporter assays and reconstitution in primary leukemia cells

   PMID:15580294

   Open questions at the time

   • Mechanism of EBF target derepression at chromatin not addressed
   • Single-lab functional data
3. 2009 High

   Demonstrated that ZNF423 is required for retinoic acid-induced differentiation by physically associating with the RARα/RXRα complex, explaining a clinically relevant determinant of neuroblastoma retinoid response.

   Evidence Large-scale RNAi screen, reciprocal Co-IP, and bidirectional gain/loss-of-function in neuroblastoma lines

   PMID:19345331

   Open questions at the time

   • Direct target genes of the ZNF423-RAR/RXR complex not defined
   • Domain mediating nuclear receptor contact unmapped
4. 2009 High

   Showed ZNF423 has a functional oncogenic role, cooperating with p210BCR/ABL to drive CML blast crisis, moving it from a transcriptional regulator to a validated cancer driver.

   Evidence Retroviral insertional mutagenesis, bone marrow transduction/transplantation, knockdown and colony assays in mice

   PMID:19234145

   Open questions at the time

   • Molecular target program underlying cooperation with BCR/ABL unresolved
5. 2012 High

   Placed ZNF423 in the DNA damage response by showing it colocalizes with TIP60, CEP164 and NPHP10 at damage foci and that its loss sensitizes cells to genotoxins, revealing a function distinct from its transcriptional roles.

   Evidence Immunofluorescence colocalization after DNA damage and siRNA knockdown with damage-sensitivity assays

   PMID:22863007

   Open questions at the time

   • Whether ZNF423 acts catalytically or as scaffold at foci unknown
   • Direct binding partners at foci not biochemically defined
6. 2013 Medium

   Identified ZNF423 as an estrogen-inducible transcriptional activator of BRCA1 and showed intronic SNPs near estrogen response elements alter this induction, linking ZNF423 genetics to hormone-responsive transcription.

   Evidence Functional genomics, luciferase reporters and estrogen induction in breast cancer cells

   PMID:23764426

   Open questions at the time

   • Mechanism by which SNPs alter ER occupancy not fully resolved
   • Direct versus indirect promoter engagement unclear
7. 2013 High

   Demonstrated oncogenic gain-of-function through a UBR5-ZNF423 fusion retaining the EBF-binding ZF29-30 domain, showing the C-terminal module is sufficient to drive transformation and tumor formation.

   Evidence Whole-transcriptome sequencing, fusion-specific knockdown, NIH3T3 transformation, and nude mouse tumorigenesis

   PMID:23878065

   Open questions at the time

   • Transcriptional targets of the fusion not enumerated
   • Contribution of UBR5 portion to oncogenicity unclear
8. 2013 High

   Connected epigenetic derepression and BMP2 signaling to aberrant ZNF423 expression that drives B-cell maturation arrest, and identified a NuRD-interacting ZNF423β isoform, mechanistically tying ZNF423 to B-precursor ALL.

   Evidence Bisulfite sequencing, in vivo B-cell differentiation assays, transactivation and BMP2 stimulation experiments

   PMID:24081948

   Open questions at the time

   • Role of the NuRD-interacting domain in repression not isolated
   • Relative contributions of hypomethylation versus BMP2 not separated
9. 2017 High

   Dissected domain-specific in vivo functions in cerebellar Purkinje progenitors, showing distinct zinc fingers govern cell-cycle exit, spindle orientation and differentiation, and that DDR markers rise when these are lost.

   Evidence Allelic series of in-frame zinc-finger deletions in mice with cell-cycle and DDR marker analysis

   PMID:28893945

   Open questions at the time

   • Molecular partners of each zinc-finger domain in progenitors undefined
   • Link between transcriptional and DDR roles unresolved
10. 2017 Medium

    Showed that promoter DNA methylation and nucleosome occupancy gate ZNF423 expression to determine adipocyte commitment, with BMP4 initiating these changes, establishing an epigenetic switch upstream of ZNF423.

    Evidence Bisulfite sequencing, MNase protection, 5-azacytidine treatment and Oil Red O differentiation assays

    PMID:29067487

    Open questions at the time

    • Downstream adipogenic targets of ZNF423 not mapped here
    • Single-lab cell-line system
11. 2019 Medium

    Defined direct ZNF423 transcriptional targets VRK1 and PBK that influence mitotic progression and chemotherapy sensitivity, with a SNP modulating effects in an estrogen/tamoxifen-dependent manner.

    Evidence ChIP, luciferase reporters, CRISPR isogenic lines, cell-cycle and viability assays

    PMID:30937657

    Open questions at the time

    • Mechanism of SNP-dependent ER coupling not fully resolved
    • Single-lab data
12. 2020 Medium

    Revealed an unanticipated post-transcriptional role: ZNF423 acts as an RNA-binding protein recognizing AU-rich elements in BCAT1 mRNA to promote autophagy via the IRE1-XBP1-RIDD axis.

    Evidence RNA-binding assays, ZNF423-BCAT1 mRNA Co-IP, and functional autophagy/pathway-inhibition assays

    PMID:32938905

    Open questions at the time

    • Domain mediating RNA binding not mapped
    • Relationship to its DNA-binding functions unknown
    • Single-lab finding
13. 2021 High

    Provided genome-wide evidence that ZNF423 occupies EBF1 sites independently of EBF1, depletes activating histone marks, selectively disrupts EBF1 transactivation, and is required for pro-B ALL viability in vivo, defining its chromatin mechanism of EBF1 antagonism.

    Evidence ChIP-seq, histone-mark/ATAC profiling, CRISPR ablation and xenotransplantation

    PMID:33646306

    Open questions at the time

    • Cofactors recruited to deplete activating marks not identified
    • Basis of selective interference with transactivation versus pioneering activity unclear
14. 2021 Medium

    Showed the rs9940645 SNP genotype reprograms AMPK signaling and metformin response in an estrogen/SERM-dependent manner, linking ZNF423 genetic variation to therapeutic outcome.

    Evidence RNA-seq, quantitative proteomics, CRISPR isogenic lines and xenograft models

    PMID:34001842

    Open questions at the time

    • Direct molecular link between SNP and AMPK pathway not established
    • Single-lab data
15. 2024 High

    Systematically resolved which ZNF423 patient variants are functionally consequential, showing allele-dependent midline brain abnormalities and reclassifying several asserted-pathogenic variants as benign, refining genotype-phenotype interpretation.

    Evidence In vivo mouse modeling of ~50 variants with quantitative neuroanatomy across 791 littermate pairs

    PMID:32925911

    Open questions at the time

    • Molecular consequences of each variant on partner binding not assayed
    • Human disease mechanism inferred from mouse phenotypes

• How ZNF423 partitions among its transcriptional (EBF1/SMAD/RAR-RXR/ER), DNA-damage-response, and RNA-binding roles within a single cell, and what governs which function dominates in a given context, remains unresolved.
• No integrated model coupling its chromatin, DDR, and RNA functions
• Domain-to-function map incomplete
• Structural basis of multi-partner selectivity unknown